Jeffrey Bluestone, PhD

Title(s)Professor, Diabetes Center
SchoolSchool of Medicine
Phone415-514-0417
ORCID ORCID Icon0000-0001-8793-7848 Additional info
vCardDownload vCard
    Other Positions
    Title(s)Professor, School of Medicine


    Collapse Biography 
    Collapse Education and Training
    Cornell Graduate School of Medical SciencePh.D.1980Immunology
    Rutgers - State UniversityM.S1977Microbiology
    Cook College, Rutgers UniversityB.S.1974Biology
    Collapse Awards and Honors
    Gould Foundation 1987  - 1989Faculty Scholar
    American Cancer Society1989Faculty Scholar
    Guggenheim Foundation1997Senior Fellowship
    Fogarty Foundation1997Senior Research Fellowship
    Cornell Medical School1998Distinguished Alumni Award
    Juvenile Diabetes Research Foundation2004Gerold & Kayla Grodsky Basic Science Award
    American Society for Transplantation2004Roche Distinguished Research Award
    Juvenile Diabetes Research Foundation2005Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award
    American Academy of Arts and Sciences2006Elected Member
    Juvenile Diabetes Research Foundation2008Scholar Award
    American Academy of Allergy, Asthma, & Immunology2010Elliott Middleton Memorial Lectureship
    National Academy of Medicine2013Elected Member
    American Society of Transplantation2015Outstanding Mentorship Award
    Federation of Clinical Immunology Societies2015President-Elect
    National Cancer Foundation2016Blue Ribbon Panel on Cancer Research (Biden Moonshot Program)

    Collapse Overview 
    Collapse Overview
    Jeffrey Bluestone, PhD, is the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and is the Director of the Hormone Research Institute in the Diabetes Center. His research over the past 25 years has focused on understanding the basic processes that control T cell activation and immune tolerance in autoimmunity and organ transplantation. He and members of his lab have developed soluble receptor antagonists; monoclonal antibodies and animals deficient in individual members of TCR and co-stimulatory pathways to define their individual roles in transplant rejection and autoimmunity including a special emphasis on a specialized subset of T cells termed “regulatory T cells” (Treg). Tregs control fundamental aspect of immune homeostasis. During the last several years, his research has adapted the animal studies using biologics and cell based therapies to develop therapeutics that can be used in humans with autoimmunity and under conditions of allotransplant rejection. Moreover, a strong role for antigen-specific Tregs have been found in these model systems and further evidence in humanized mice and transplant patients that alloantigen-specific Tregs are more effective. Thus, the major goal of this work is to identify the antigen-specificity of thymic- and peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, his lab initiated several projects to determine mechanisms that control Treg stability. The goal is to develop approaches using pharmacogenomics to either stabilize or destabilize Tregs in autoimmunity and cancer.

    In March 2010 Dr. Bluestone was appointed executive vice chancellor and provost at the University of California San Francisco (UCSF) serving as chief academic officer guiding the research and academic enterprise advancing the campus priorities in close collaboration with the chancellor and the campus leadership teams, and to oversee the campus ethics and compliance enterprise. Previously he served in a number of posts including Director of theUCSF Diabetes Center, as Director of the Immune Tolerance Network.

    In June 2008 Dr. Bluestone served as interim vice chancellor of research; directing the advancement of cross-campus research initiatives, such as enhancing core research facilities. In this capacity, he played a leading role in coordinating and integrating current research cores. He worked also to strengthen external research partnerships, particularly with industry, and focused on facilitating the translation of UCSF discoveries into public benefit.

    In 2009, Dr. Bluestone led the UCSF committee to strategize and secure funds available through the American Recovery and Reinvestment Act, making the campus one of the top institutional recipients in the nation of science-based stimulus funds.

    Dr. Bluestone joined the UCSF faculty in 2000. He is an international leader in the field of immunotherapy, with a stellar record of scholarly achievement and a decade of significant contributions to the research enterprise at UCSF, including the creation and directorship of an integrated UCSF Diabetes Center to focus on translating basic research in both type 1 and type 2 diabetes into improved therapies for patients. He also founded and directed the Immune Tolerance Network, a consortium of more than 1,000 of the world’s leading scientific researchers and clinical specialists from nearly 50 institutions, with the mission of testing new therapies to promote immune tolerance in transplantation, autoimmune diseases, asthma and allergic diseases.

    As a research scientist, Dr. Bluestone has helped clarify the body’s immune response on a molecular level. His systematic investigation has catalyzed recent progress in stem cell research, islet cell transplantation and immune tolerance therapies – experimentation that has formidably translated into drugs to treat human disease.

    Through his 30-year scientific career, he has authored more than 300 peer-reviewed publications that include prominent papers in Nature, Nature Immunology, and the Journal of Immunology and Diabetes. He has received numerous accolades for his work, including his 2006 election to the American Academy of Arts and Sciences, the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation, and the distinguished alumni award from the Cornell Graduate School of Medical Science.

    Prior to joining UCSF, Bluestone was at the University of Chicago, where he was a member of the Ben May Institute for Cancer Research, rising over 13 years from an associate professor to the director of the institute. He had previously worked for seven years in various roles at the National Cancer Institute of the National Institutes of Health, ultimately becoming a senior investigator in the Immunology Branch of the National Cancer Institute.

    Dr. Bluestone earned both his BS in biology and his MS in microbiology from Rutgers State University, and his PhD in immunology from the Cornell Graduate School of Medical Science (Sloan-Kettering Division).
    Collapse In The News

    Collapse Research 
    Collapse Research Activities and Funding
    Designer Tregs for restoring tolerance in patients with type 1 diabetes
    NIH UC4DK116264Sep 20, 2017 - Aug 31, 2021
    Role: Principal Investigator
    Using human stem cell-derived thymic epithelium to remodel T1D immune tolerance
    NIH U01DK107383Jul 1, 2016 - Dec 31, 2020
    Role: Co-Principal Investigator
    Using human stem cell-derived thymic epithelium to remodel T1D immune tolerance
    NIH/NIDDK R01DK107383Jul 1, 2016 - Jun 30, 2020
    Role: Co-Principal Investigator
    Disruption of T cell tolerance in type 1 diabetes
    NIH P01AI118688Jun 8, 2016 - May 31, 2021
    Role: Co-Investigator
    Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation
    NIH U01AI110658Jun 1, 2014 - May 31, 2021
    Role: Co-Principal Investigator
    Autoimmunity Center of Excellence Clinical Research Program
    NIH UM1AI110498May 1, 2014 - Apr 30, 2020
    Role: Co-Investigator
    Role of Innate Lymphoid Cells in Autoimmunity
    NIH R21AI107328Dec 1, 2013 - Nov 30, 2015
    Role: Principal Investigator
    Donor-Specific Regulatory T Cell Therapy in Liver Transplantation
    NIH R34AI095135Apr 1, 2012 - Mar 31, 2014
    Role: Co-Principal Investigator
    Expanding beta-cell mass
    NIH U01DK089541Sep 15, 2010 - Jun 30, 2015
    Role: Co-Principal Investigator
    Role of Notch 1 in Immune Tolerance
    NIH R21AI059979Apr 1, 2004 - Mar 31, 2007
    Role: Principal Investigator
    Autoimmunity Center of Excellence
    NIH U19AI056388Sep 30, 2003 - Apr 30, 2015
    Role: Co-Investigator
    Diabetes Research Center
    NIH P30DK063720Sep 1, 2002 - Mar 31, 2021
    Role: Co-Principal Investigator
    Conf on Mechanism and Applications of Immune Tolerance
    NIH R13AI051294Apr 1, 2002 - Mar 31, 2003
    Role: Principal Investigator
    Spontaneous Autoimmune Model of Peripheral Neuropathy
    NIH R01AI050834Dec 15, 2001 - Nov 30, 2012
    Role: Principal Investigator
    Immune tolerance network: lung transplantation
    NIH N01AI15416-20-0-10Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: liver transplantation
    NIH N01AI15416-20-0-11Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Systemic lupus rythematosus (SLE)
    NIH N01AI15416-20-0-12Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Kidney, Liver and Bone Marrow Transplantation
    NIH N01AI15416-20-0-2Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Food Allergy
    NIH N01AI15416-20-0-3Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Type 1 diabetes
    NIH N01AI15416-20-0-4Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Multiple sclerosis
    NIH N01AI15416-20-0-5Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Rheumatoid arthritis
    NIH N01AI15416-20-0-6Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Autoimmune diseases: Vasculitis
    NIH N01AI15416-20-0-7Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Islet cell transplantation
    NIH N01AI15416-20-0-8Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: heart tranplantation
    NIH N01AI15416-20-0-9Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: liver transplantation
    NIH N01AI15416-23-0-11Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Systemic lupus rythematosus (SLE)
    NIH N01AI15416-23-0-12Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: kidney transplantation
    NIH N01AI15416-23-0-13Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    IImmune Tolerance Network: Airborne Allergens and Allergic Rhintitis
    NIH N01AI15416-23-0-14Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Food Allergy
    NIH N01AI15416-23-0-3Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Type 1 diabetes
    NIH N01AI15416-23-0-4Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Multiple sclerosis
    NIH N01AI15416-23-0-5Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    FASEB SUMMER CONFERENCE--LYMPHOCYTES AND ANTIBODIES
    NIH R13AI047114Jun 1, 2000 - May 31, 2001
    Role: Principal Investigator
    Immunomodulation of transplant rejection by Anti-CD3 mAb
    NIH R01AI046643Mar 1, 2000 - Nov 30, 2016
    Role: Principal Investigator
    IMMUNOMODULATION OF TRANSPLANT REJECTION BY ANTI-CD3 MAB
    NIH R37AI046643Mar 1, 2000 - Feb 28, 2011
    Role: Principal Investigator
    MOFLO MULTILASER FLOW CYTOMETER
    NIH S10RR014884Mar 1, 2000 - Feb 28, 2001
    Role: Principal Investigator
    COLLABORATIVE NETWORK FOR CLINICAL RES ON IMMUNE TOLERAN
    NIH/NIAID N01AI095380Sep 30, 1999 - Sep 29, 2006
    Role: Principal Investigator
    TOLERANCE OF ISLET CELL GRAFT
    NIH R01DK055351Jun 15, 1999 - May 31, 2003
    Role: Principal Investigator
    CTLA 4 ANTAGONISM DURING T CELL ACTIVATION
    NIH F33AI009895Mar 22, 1998
    Role: Principal Investigator
    Immune Tolerance and Autoimmunity
    NIH P01AI035297Sep 1, 1997 - Jul 31, 2012
    Role: Co-Investigator
    SCOR in Cellular and Molecular Mechanisms of Asthma
    NIH P50HL056399Sep 30, 1996 - Aug 31, 2006
    Role: Co-Principal Investigator
    IMMUNOREGULATION OF IDDM
    NIH P01DK049799Jun 15, 1995 - May 31, 2000
    Role: Co-Investigator
    COSTIMULATION IN PERIPHERAL T CELL TOLERANCE AND ANERGY
    NIH P01AI035294Sep 1, 1993 - Aug 31, 2001
    Role: Principal Investigator
    IMMUNOMODULATION OF TRANSPLANT REJECTION
    NIH P01AI029531Jun 1, 1990 - Aug 31, 2000
    Role: Principal Investigator
    IMMUNOBIOLOGY OF TCR GAMMA/DELTA T-CELLS
    NIH R01AI026847Sep 1, 1988 - Aug 31, 1999
    Role: Principal Investigator
    IN VIVO POTENTIATION OF IMMUNE RESPONSES
    NIH R01CA049260Aug 5, 1988 - Jul 31, 1995
    Role: Principal Investigator
    Interdisciplinary Training Program in Immunology
    NIH T32AI007090Jul 1, 1979 - Jun 30, 2024
    Role: Co-Principal Investigator
    Cancer Center Support Grant
    NIH P30CA014599Feb 1, 1977 - Mar 31, 2018
    Role: Co-Investigator
    IMMUNITY AND CANCER
    NIH P01CA019266Jun 1, 1976 - Mar 31, 1996
    Role: Co-Investigator
    Immune Tolerance Network: Autoimmune Diseases
    NIH/NIAID N01AI15416
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Global Health

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021 Jun 29. Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Gleevec Trial Study Group . PMID: 34214479.
      View in: PubMed   Mentions:    Fields:    
    2. The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Front Immunol. 2021; 12:639818. Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, Congrave-Wilson Z, Roth TL, Eyquem J, Van Gool F, Marson A, Perez L, Wells JA, Bluestone JA, Tang Q. PMID: 33833759.
      View in: PubMed   Mentions: 1     Fields:    
    3. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends Immunol. 2021 04; 42(4):293-311. Kang JH, Bluestone JA, Young A. PMID: 33714688.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. At the Heart of Immune Checkpoint Inhibitor-Induced Immune Toxicity. Cancer Discov. 2021 Mar; 11(3):537-539. Young A, Bluestone JA. PMID: 33653918.
      View in: PubMed   Mentions:    Fields:    
    5. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020 12 10; 183(6):1479-1495.e20. Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, Voillet V, Duvvuri VR, Scherler K, Troisch P, Baloni P, Qin G, Smith B, Kornilov SA, Rostomily C, Xu A, Li J, Dong S, Rothchild A, Zhou J, Murray K, Edmark R, Hong S, Heath JE, Earls J, Zhang R, Xie J, Li S, Roper R, Jones L, Zhou Y, Rowen L, Liu R, Mackay S, O'Mahony DS, Dale CR, Wallick JA, Algren HA, Zager MA, ISB-Swedish COVID19 Biobanking Unit , Wei W, Price ND, Huang S, Subramanian N, Wang K, Magis AT, Hadlock JJ, Hood L, Aderem A, Bluestone JA, Lanier LL, Greenberg PD, Gottardo R, Davis MM, Goldman JD, Heath JR. PMID: 33171100.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    6. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020 10 02; 5(52). Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA. PMID: 33008914.
      View in: PubMed   Mentions: 9     Fields:    
    7. Solving the Puzzle of Immune Tolerance for ß-Cell Replacement Therapy for Type 1 Diabetes. Cell Stem Cell. 2020 10 01; 27(4):505-507. Bluestone JA, Tang Q. PMID: 33007232.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    8. Functional CRISPR dissection of gene networks controlling human regulatory T cell identity. Nat Immunol. 2020 11; 21(11):1456-1466. Schumann K, Raju SS, Lauber M, Kolb S, Shifrut E, Cortez JT, Skartsis N, Nguyen VQ, Woo JM, Roth TL, Yu R, Nguyen MLT, Simeonov DR, Nguyen DN, Targ S, Gate RE, Tang Q, Bluestone JA, Spitzer MH, Ye CJ, Marson A. PMID: 32989329.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    9. Tolerance in the Age of Immunotherapy. N Engl J Med. 2020 09 17; 383(12):1156-1166. Bluestone JA, Anderson M. PMID: 32937048.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    10. Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories. bioRxiv. 2020 Jul 31. Su Y, Chen D, Lausted C, Yuan D, Choi J, Dai C, Voillet V, Scherler K, Troisch P, Duvvuri VR, Baloni P, Qin G, Smith B, Kornilov S, Rostomily C, Xu A, Li J, Dong S, Rothchild A, Zhou J, Murray K, Edmark R, Hong S, Jones L, Zhou Y, Roper R, Mackay S, O'Mahony DS, Dale CR, Wallick JA, Algren HA, Michael ZA, Magis A, Wei W, Price ND, Huang S, Subramanian N, Wang K, Hadlock J, Hood L, Aderem A, Bluestone JA, Lanier LL, Greenberg P, Gottardo R, Davis MM, Goldman JD, Heath JR. PMID: 32766585.
      View in: PubMed   Mentions:
    11. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 2020 05 23; 395(10237):1627-1639. Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, Tang Q, Guinan EC, Battaglia M, Burlingham WJ, Roberts ISD, Streitz M, Josien R, Böger CA, Scottà C, Markmann JF, Hester JL, Juerchott K, Braudeau C, James B, Contreras-Ruiz L, van der Net JB, Bergler T, Caldara R, Petchey W, Edinger M, Dupas N, Kapinsky M, Mutzbauer I, Otto NM, Öllinger R, Hernandez-Fuentes MP, Issa F, Ahrens N, Meyenberg C, Karitzky S, Kunzendorf U, Knechtle SJ, Grinyó J, Morris PJ, Brent L, Bushell A, Turka LA, Bluestone JA, Lechler RI, Schlitt HJ, Cuturi MC, Schlickeiser S, Friend PJ, Miloud T, Scheffold A, Secchi A, Crisalli K, Kang SM, Hilton R, Banas B, Blancho G, Volk HD, Lombardi G, Wood KJ, Geissler EK. PMID: 32446407.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    12. CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature. 2020 06; 582(7812):416-420. Cortez JT, Montauti E, Shifrut E, Gatchalian J, Zhang Y, Shaked O, Xu Y, Roth TL, Simeonov DR, Zhang Y, Chen S, Li Z, Woo JM, Ho J, Vogel IA, Prator GY, Zhang B, Lee Y, Sun Z, Ifergan I, Van Gool F, Hargreaves DC, Bluestone JA, Marson A, Fang D. PMID: 32499641.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    13. Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. Cell. 2020 04 30; 181(3):728-744.e21. Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, Yu R, Nguyen MLT, Lee Y, Truong A, Hiatt J, Wu D, Nguyen DN, Goodman D, Bluestone JA, Ye CJ, Roybal K, Shifrut E, Marson A. PMID: 32302591.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    14. Accelerating the development of innovative cellular therapy products for the treatment of cancer. Cytotherapy. 2020 05; 22(5):239-246. Stewart MD, Keane A, Butterfield LH, Levine BL, Thompson B, Xu Y, Ramsborg C, Lee A, Kalos M, Koerner C, Moore T, Markovic I, Lasiter L, Ibrahim R, Bluestone J, Sigal E, Allen J. PMID: 32199724.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Cutting Edge: IL-6-Driven Immune Dysregulation Is Strictly Dependent on IL-6R a-Chain Expression. J Immunol. 2020 02 15; 204(4):747-751. Mufazalov IA, Andruszewski D, Schelmbauer C, Heink S, Blanfeld M, Masri J, Tang Y, Schüler R, Eich C, Wunderlich FT, Karbach SH, Bluestone JA, Korn T, Waisman A. PMID: 31924653.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    16. New Frontiers in the Treatment of Type 1 Diabetes. Cell Metab. 2020 01 07; 31(1):46-61. Warshauer JT, Bluestone JA, Anderson MS. PMID: 31839487.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    17. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat Biotechnol. 2020 01; 38(1):44-49. Nguyen DN, Roth TL, Li PJ, Chen PA, Apathy R, Mamedov MR, Vo LT, Tobin VR, Goodman D, Shifrut E, Bluestone JA, Puck JM, Szoka FC, Marson A. PMID: 31819258.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    18. Treg cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020 03; 20(3):158-172. Raffin C, Vo LT, Bluestone JA. PMID: 31811270.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    19. Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model. PLoS One. 2019; 14(10):e0217728. Holohan DR, Van Gool F, Bluestone JA. PMID: 31647813.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    20. Next-generation regulatory T cell therapy. Nat Rev Drug Discov. 2019 10; 18(10):749-769. Ferreira LMR, Muller YD, Bluestone JA, Tang Q. PMID: 31541224.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    21. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 08 15; 381(7):603-613. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group . PMID: 31180194.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCellsCTClinical Trials
    22. NextGen cell-based immunotherapies in cancer and other immune disorders. Curr Opin Immunol. 2019 08; 59:79-87. Azimi CS, Tang Q, Roybal KT, Bluestone JA. PMID: 31071513.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    23. A Mutation in the Transcription Factor Foxp3 Drives T Helper 2 Effector Function in Regulatory T Cells. Immunity. 2019 02 19; 50(2):362-377.e6. Van Gool F, Nguyen MLT, Mumbach MR, Satpathy AT, Rosenthal WL, Giacometti S, Le DT, Liu W, Brusko TM, Anderson MS, Rudensky AY, Marson A, Chang HY, Bluestone JA. PMID: 30709738.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    24. Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 03; 71(3):431-440. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD, Autoimmunity Centers of Excellence . PMID: 30277008.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    25. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Front Med (Lausanne). 2018; 5:351. Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. PMID: 30631766.
      View in: PubMed   Mentions:
    26. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res. 2018 12; 6(12):1445-1452. Young A, Quandt Z, Bluestone JA. PMID: 30510057.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    27. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Med. 2018 10 31; 10(1):79. Bucktrout SL, Bluestone JA, Ramsdell F. PMID: 30376867.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    28. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. J Allergy Clin Immunol. 2018 12; 142(6):1710-1718. Esensten JH, Muller YD, Bluestone JA, Tang Q. PMID: 30367909.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    29. Treg cells-the next frontier of cell therapy. Science. 2018 10 12; 362(6411):154-155. Bluestone JA, Tang Q. PMID: 30309932.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    30. Chance favours the prepared mind. Nat Rev Immunol. 2018 09; 18(9):541. Bluestone JA. PMID: 30018454.
      View in: PubMed   Mentions:    Fields:    
    31. Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. J Immunol. 2018 10 01; 201(7):2094-2106. Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC. PMID: 30104245.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    32. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018 07 06; 3(25). Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA. PMID: 29980618.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    33. Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature. 2018 07; 559(7715):E13. Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A. PMID: 29899441.
      View in: PubMed   Mentions:    Fields:    
    34. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat Med. 2018 07; 24(7):1005-1014. Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL, Garcia KC, Crellin NK, Rondon IJ, Bluestone JA. PMID: 29942088.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    35. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018 08; 67(8):1471-1480. Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. PMID: 29937434.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansAnimals
    36. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Rep. 2018 06 12; 23(11):3262-3274. Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M. PMID: 29898397.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    37. Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges. Cell Stem Cell. 2018 Jun 01; 22(6):810-823. Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M. PMID: 29859172.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    38. Pathological conversion of regulatory T cells is associated with loss of allotolerance. Sci Rep. 2018 05 04; 8(1):7059. Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, Bluestone JA, Dana R. PMID: 29728574.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    39. Revealing the specificity of regulatory T cells in murine autoimmune diabetes. Proc Natl Acad Sci U S A. 2018 05 15; 115(20):5265-5270. Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju CH, Sterling T, Nakayama M, Robinson WH, Bluestone JA, Anderson MS, Tang Q. PMID: 29712852.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    40. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018 03 02; 359(6379):1037-1042. Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC. PMID: 29496879.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    41. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Front Immunol. 2017; 8:1844. Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grzes D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. PMID: 29379498.
      View in: PubMed   Mentions: 12     Fields:    
    42. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 11; 18(11):e653-e706. Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. PMID: 29208398.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    43. Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes. Front Immunol. 2017; 8:1313. Yeh WI, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, Mathews CE, Bluestone JA, Brusko TM. PMID: 29123516.
      View in: PubMed   Mentions: 20     Fields:    
    44. Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature. 2017 09 07; 549(7670):111-115. Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A. PMID: 28854172.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    45. Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017 08 04; 23(8):1004. June CH, Warshauer JT, Bluestone JA. PMID: 28777789.
      View in: PubMed   Mentions: 1     Fields:    
    46. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017 05 05; 23(5):540-547. June CH, Warshauer JT, Bluestone JA. PMID: 28475571.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCells
    47. Targeting ABL-IRE1a Signaling Spares ER-Stressed Pancreatic ß Cells to Reverse Autoimmune Diabetes. Cell Metab. 2017 05 02; 25(5):1207. Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR. PMID: 28467938.
      View in: PubMed   Mentions: 10     Fields:    
    48. Targeting ABL-IRE1a Signaling Spares ER-Stressed Pancreatic ß Cells to Reverse Autoimmune Diabetes. Cell Metab. 2017 Apr 04; 25(4):883-897.e8. Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR. PMID: 28380378.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    49. FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance. J Immunol. 2017 02 01; 198(3):979-980. Bluestone JA. PMID: 28115585.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    50. Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Mol Ther Methods Clin Dev. 2017 Mar 17; 4:178-191. Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, Bluestone JA, Haller MJ, Brusko TM. PMID: 28345003.
      View in: PubMed   Mentions:
    51. Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol. 2017 Jan 24; 12:305-330. Esensten JH, Bluestone JA, Lim WA. PMID: 27959633.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    52. CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016 05 17; 44(5):973-88. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. PMID: 27192564.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansAnimalsCells
    53. Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016 05 01; 196(9):3966. Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF. PMID: 27183651.
      View in: PubMed   Mentions: 1     Fields:    
    54. Regulatory T cell therapy for type 1 diabetes: May the force be with you. J Autoimmun. 2016 07; 71:78-87. Gitelman SE, Bluestone JA. PMID: 27133597.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    55. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. 2016 06; 59(6):1153-61. Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR, ITN START Study Team . PMID: 27053235.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    56. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol. 2016 Mar; 16(3):149-63. DuPage M, Bluestone JA. PMID: 26875830.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansAnimalsCells
    57. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016 Mar 01; 196(5):2051-2062. Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF. PMID: 26826243.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    58. Inducing and Administering Tregs to Treat Human Disease. Front Immunol. 2015; 6:654. Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC. PMID: 26834735.
      View in: PubMed   Mentions: 24     Fields:    
    59. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25; 7(315):315ra189. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. PMID: 26606968.
      View in: PubMed   Mentions: 280     Fields:    Translation:HumansCellsCTClinical Trials
    60. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016 Feb; 117(2):66-83. Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR. PMID: 26597321.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimals
    61. Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell. 2015 Oct 12; 28(4):401-402. Holohan DR, Lee JC, Bluestone JA. PMID: 26461084.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    62. Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol. 2015 Dec; 37:11-20. Spence A, Klementowicz JE, Bluestone JA, Tang Q. PMID: 26432763.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    63. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015 Aug 18; 112(33):10437-42. Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A. PMID: 26216948.
      View in: PubMed   Mentions: 215     Fields:    Translation:HumansCells
    64. Interleukin-33 and Interferon-? Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity. 2015 Jul 21; 43(1):161-74. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM. PMID: 26092469.
      View in: PubMed   Mentions: 158     Fields:    Translation:AnimalsCells
    65. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. J Immunol. 2015 Jul 01; 195(1):145-55. Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM. PMID: 25994968.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCells
    66. IL-2: Change Structure … Change Function. Immunity. 2015 May 19; 42(5):779-81. Bluestone JA, Crellin N, Trotta E. PMID: 25992850.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    67. T cells in the control of organ-specific autoimmunity. J Clin Invest. 2015 Jun; 125(6):2250-60. Bluestone JA, Bour-Jordan H, Cheng M, Anderson M. PMID: 25985270.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    68. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets. 2015; 19(8):1091-103. Bluestone JA, Trotta E, Xu D. PMID: 25881491.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    69. Immunotherapy: making the case for precision medicine. Sci Transl Med. 2015 Mar 25; 7(280):280ed3. Bluestone JA, Tang Q. PMID: 25810308.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    70. The immune system in Duchenne muscular dystrophy: Friend or foe. Rare Dis. 2015; 3(1):e1010966. Villalta SA, Rosenberg AS, Bluestone JA. PMID: 26481612.
      View in: PubMed   Mentions:
    71. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity. 2015 Feb 17; 42(2):227-238. DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA. PMID: 25680271.
      View in: PubMed   Mentions: 91     Fields:    Translation:AnimalsCells
    72. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol. 2015 Feb; 16(2):188-96. Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, Bluestone JA, Turka LA. PMID: 25559257.
      View in: PubMed   Mentions: 181     Fields:    Translation:AnimalsCells
    73. Innate antiviral host defense attenuates TGF-ß function through IRF3-mediated suppression of Smad signaling. Mol Cell. 2014 Dec 18; 56(6):723-37. Xu P, Bailey-Bucktrout S, Xi Y, Xu D, Du D, Zhang Q, Xiang W, Liu J, Melton A, Sheppard D, Chapman HA, Bluestone JA, Derynck R. PMID: 25526531.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    74. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell. 2015 Feb 05; 16(2):148-57. Szot GL, Yadav M, Lang J, Kroon E, Kerr J, Kadoya K, Brandon EP, Baetge EE, Bour-Jordan H, Bluestone JA. PMID: 25533131.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    75. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood. 2014 Dec 04; 124(24):3572-6. Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, Locksley RM, Bluestone JA. PMID: 25323825.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    76. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med. 2014 Oct 15; 6(258):258ra142. Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG, Margeta M, Spencer MJ, Bluestone JA. PMID: 25320234.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimalsCells
    77. Aberrant innate immune activation following tissue injury impairs pancreatic regeneration. PLoS One. 2014; 9(7):e102125. Folias AE, Penaranda C, Su AL, Bluestone JA, Hebrok M. PMID: 25010227.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    78. Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol. 2014 Jun; 44(6):1737-46. Stumpf M, Zhou X, Chikuma S, Bluestone JA. PMID: 24648182.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    79. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014 Jan; 20(1):62-8. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H. PMID: 24362934.
      View in: PubMed   Mentions: 343     Fields:    Translation:HumansAnimalsCells
    80. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity. 2013 Nov 14; 39(5):949-62. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA. PMID: 24238343.
      View in: PubMed   Mentions: 155     Fields:    Translation:AnimalsCells
    81. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med. 2013 Nov 01; 3(11). Tang Q, Bluestone JA. PMID: 24186492.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansAnimalsCells
    82. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):306-16. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, START Study Team . PMID: 24622416.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    83. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol. 2013; 4:232. Yadav M, Stephan S, Bluestone JA. PMID: 23966994.
      View in: PubMed   Mentions: 87     Fields:    
    84. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med. 2013 Jul 29; 210(8):1603-19. Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. PMID: 23878307.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    85. Production of a-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol. 2013 Jul; 11(7):e1001610. Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA. PMID: 23874157.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCells
    86. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol. 2013 Aug 15; 191(4):1594-605. de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. PMID: 23858035.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    87. Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background. J Autoimmun. 2013 Sep; 45:58-67. Bour-Jordan H, Thompson HL, Giampaolo JR, Davini D, Rosenthal W, Bluestone JA. PMID: 23850635.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    88. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 62(11):3766-74. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team . PMID: 23835333.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    89. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes. 2013 Aug; 62(8):2870-8. Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA. PMID: 23835340.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    90. The microRNA cluster miR-17~92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol. 2013 Aug; 14(8):840-8. Baumjohann D, Kageyama R, Clingan JM, Morar MM, Patel S, de Kouchkovsky D, Bannard O, Bluestone JA, Matloubian M, Ansel KM, Jeker LT. PMID: 23812098.
      View in: PubMed   Mentions: 95     Fields:    Translation:AnimalsCells
    91. DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability. PLoS One. 2013; 8(5):e66282. Jeker LT, Zhou X, Blelloch R, Bluestone JA. PMID: 23741528.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    92. MicroRNA regulation of T-cell differentiation and function. Immunol Rev. 2013 May; 253(1):65-81. Jeker LT, Bluestone JA. PMID: 23550639.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    93. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013 Apr 03; 5(179):179ps7. Fischbach MA, Bluestone JA, Lim WA. PMID: 23552369.
      View in: PubMed   Mentions: 123     Fields:    Translation:Humans
    94. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013 Apr; 14(4):307-8. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF. PMID: 23507634.
      View in: PubMed   Mentions: 224     Fields:    Translation:HumansAnimalsCells
    95. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013 Apr; 13(4):243-56. Herold KC, Vignali DA, Cooke A, Bluestone JA. PMID: 23524461.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansAnimalsCells
    96. Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. J Immunol. 2013 May 01; 190(9):4470-3. Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF. PMID: 23543754.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    97. Immune therapy and ß-cell death in type 1 diabetes. Diabetes. 2013 May; 62(5):1676-80. Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC. PMID: 23423576.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    98. The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol. 2013 Feb 01; 190(3):961-9. Stumpf M, Zhou X, Bluestone JA. PMID: 23293354.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    99. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol. 2012 Nov 01; 4(11). Bluestone JA, Bour-Jordan H. PMID: 23125012.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    100. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int. 2012 Dec; 25(12):1257-67. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. PMID: 22994802.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    101. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 2012 Sep 24; 209(10):1713-22, S1-19. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, Bluestone JA. PMID: 22966003.
      View in: PubMed   Mentions: 292     Fields:    Translation:AnimalsCells
    102. Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. . 2012 Aug 08; 12(8):4018-24. Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM. PMID: 22784189.
      View in: PubMed   Mentions:
    103. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 2012 Jul 10; 22(1):7-8. Bluestone JA, Small EJ. PMID: 22789534.
      View in: PubMed   Mentions: 1     Fields:    
    104. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12668-73. Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LS, Bluestone JA, Abbas AK, Dooms H. PMID: 22733744.
      View in: PubMed   Mentions: 56     Fields:    Translation:AnimalsCells
    105. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs ß-cell function. Diabetes. 2012 Sep; 61(9):2340-8. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ, Diabetes TrialNet and the Immune Tolerance Network . PMID: 22721971.
      View in: PubMed   Mentions: 138     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    106. MicroRNA 10a marks regulatory T cells. PLoS One. 2012; 7(5):e36684. Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone JA. PMID: 22629323.
      View in: PubMed   Mentions: 58     Fields:    Translation:AnimalsCells
    107. NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS One. 2012; 7(4):e36011. Beilke JN, Meagher CT, Hosiawa K, Champsaur M, Bluestone JA, Lanier LL. PMID: 22558306.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    108. A resource for the conditional ablation of microRNAs in the mouse. Cell Rep. 2012 Apr 19; 1(4):385-91. Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R, Richards H, Li Z, Adler D, Yoshinaga Y, Martinez M, Nefadov M, Abbas AK, Weiss A, Lanier LL, de Jong PJ, Bluestone JA, Srivastava D, McManus MT. PMID: 22570807.
      View in: PubMed   Mentions: 90     Fields:    Translation:AnimalsCells
    109. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a007807. Jeker LT, Bour-Jordan H, Bluestone JA. PMID: 22393537.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    110. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol. 2012 Feb; 4(1):11-21. Tang Q, Bluestone JA, Kang SM. PMID: 22170955.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    111. The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med. 2011 Dec 01; 365(22):2129-31. Bluestone JA. PMID: 22129258.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    112. A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse. J Immunol. 2011 Nov 15; 187(10):4947-53. Tada A, Shimada A, Yamada T, Oikawa Y, Yamada Y, Okubo Y, Irie J, Bluestone JA, Itoh H. PMID: 21967896.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    113. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. J Immunol. 2011 Oct 01; 187(7):3466-74. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. PMID: 21934098.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    114. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol. 2011 Aug 14; 12(9):898-907. Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, Sommer D, Debey-Pascher S, Endl E, Limmer A, Hippen KL, Blazar BR, Balderas R, Quast T, Waha A, Mayer G, Famulok M, Knolle PA, Wickenhauser C, Kolanus W, Schermer B, Bluestone JA, Barry SC, Sparwasser T, Riley JL, Schultze JL. PMID: 21841785.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    115. Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med. 2011 Aug 10; 3(95):95fs1. Herold KC, Bluestone JA. PMID: 21832236.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    116. Control of TH17 cells occurs in the small intestine. Nature. 2011 Jul 17; 475(7357):514-8. Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, Flavell RA. PMID: 21765430.
      View in: PubMed   Mentions: 247     Fields:    Translation:AnimalsCells
    117. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol. 2011 Aug 15; 187(4):2015-22. Penaranda C, Tang Q, Bluestone JA. PMID: 21742976.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    118. Regulatory T cells: stability revisited. Trends Immunol. 2011 Jul; 32(7):301-6. Bailey-Bucktrout SL, Bluestone JA. PMID: 21620768.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    119. Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice. J Immunol. 2011 Jul 01; 187(1):325-36. Rainbow DB, Moule C, Fraser HI, Clark J, Howlett SK, Burren O, Christensen M, Moody V, Steward CA, Mohammed JP, Fusakio ME, Masteller EL, Finger EB, Houchins JP, Naf D, Koentgen F, Ridgway WM, Todd JA, Bluestone JA, Peterson LB, Mattner J, Wicker LS. PMID: 21613616.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    120. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/?B7 family. Immunol Rev. 2011 May; 241(1):180-205. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. PMID: 21488898.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansAnimalsCells
    121. Mechanisms of tolerance. Immunol Rev. 2011 May; 241(1):5-19. Bluestone JA. PMID: 21488886.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    122. How does type 1 diabetes develop?: the notion of homicide or ß-cell suicide revisited. Diabetes. 2011 May; 60(5):1370-9. Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. PMID: 21525508.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCells
    123. Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts. J Surg Res. 2011 Jul; 169(1):e69-75. Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone JA, Kang SM. PMID: 21571317.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    124. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011 Apr 01; 186(7):3918-26. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM. PMID: 21368230.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCells
    125. Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol. 2011 Apr 01; 186(7):3831-5. Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone JA, Singh B. PMID: 21357258.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    126. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One. 2011 Jan 06; 6(1):e15868. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. PMID: 21253593.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    127. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. PMID: 20978464.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    128. Expression of avß8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest. 2010 Dec; 120(12):4436-44. Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone JA, Sheppard D. PMID: 21099117.
      View in: PubMed   Mentions: 66     Fields:    Translation:AnimalsCells
    129. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol. 2010 Nov; 10(11):797-803. Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. PMID: 20972473.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    130. Clusterin synergizes with IL-2 for the expansion and IFN-? production of natural killer cells. J Leukoc Biol. 2010 Nov; 88(5):955-63. Sonn CH, Yu YB, Hong YJ, Shim YJ, Bluestone JA, Min BH, Lee KM. PMID: 20729304.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    131. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010 Aug 30; 207(9):1871-8. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E. PMID: 20679400.
      View in: PubMed   Mentions: 175     Fields:    Translation:AnimalsCells
    132. Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant. 2010 Aug; 15(4):441-8. Turka LA, Wood K, Bluestone JA. PMID: 20631613.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    133. FK506 causes cellular and functional defects in human natural killer cells. J Leukoc Biol. 2010 Dec; 88(6):1089-97. Kim TJ, Kim N, Kang HJ, Kim EO, Kim ST, Ahn HS, Bluestone JA, Lee KM. PMID: 20671192.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    134. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 2010 Jul 22; 5(7):e11726. Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA. PMID: 20668510.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    135. Small RNA regulators of T cell-mediated autoimmunity. J Clin Immunol. 2010 May; 30(3):347-57. Jeker LT, Bluestone JA. PMID: 20393792.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    136. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010 Apr 29; 464(7293):1293-300. Bluestone JA, Herold K, Eisenbarth G. PMID: 20432533.
      View in: PubMed   Mentions: 373     Fields:    Translation:HumansAnimals
    137. Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor. Immunology. 2010 Aug; 130(4):545-55. Kim TJ, Kim N, Kim EO, Choi JR, Bluestone JA, Lee KM. PMID: 20406306.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    138. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes. 2010 Jun; 59(6):1461-8. Penaranda C, Tang Q, Ruddle NH, Bluestone JA. PMID: 20299465.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    139. Ten years of the Immune Tolerance Network: an integrated clinical research organization. Sci Transl Med. 2010 Feb 17; 2(19):19cm7. Bluestone JA, Krensky AM, Turka LA, Rotrosen D, Matthews JB. PMID: 20371484.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    140. Regulatory T cells directed to the site of the action. Proc Natl Acad Sci U S A. 2009 Dec 08; 106(49):20553-4. Brusko TM, Bluestone JA. PMID: 19955436.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    141. Autoimmunity. Curr Opin Immunol. 2009 Dec; 21(6):579-81. Bluestone JA, Kuchroo V. PMID: 19879742.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    142. Is antigen specificity of autoreactive T cells the key to islet entry? Immunity. 2009 Oct 16; 31(4):534-6. Penaranda C, Bluestone JA. PMID: 19833083.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    143. The functional plasticity of T cell subsets. Nat Rev Immunol. 2009 11; 9(11):811-6. Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B. PMID: 19809471.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansAnimalsCells
    144. How suppressor cells led to anergy, costimulation, and beyond. J Immunol. 2009 Oct 01; 183(7):4147-9. Bour-Jordan H, Bluestone JA. PMID: 19767564.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    145. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5. Esensten JH, Wofsy D, Bluestone JA. PMID: 19798031.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimalsCells
    146. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009 Nov; 10(11):1185-92. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. PMID: 19783989.
      View in: PubMed   Mentions: 300     Fields:    Translation:AnimalsCells
    147. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009 Sep; 10(9):1000-7. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. PMID: 19633673.
      View in: PubMed   Mentions: 585     Fields:    Translation:AnimalsCells
    148. Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice. Endocrinology. 2009 Oct; 150(10):4531-40. Norquay LD, D'Aquino KE, Opare-Addo LM, Kuznetsova A, Haas M, Bluestone JA, White MF. PMID: 19574401.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    149. Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome. J Immunol. 2009 Jul 15; 183(2):953-61. Perruche S, Zhang P, Maruyama T, Bluestone JA, Saas P, Chen W. PMID: 19561097.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    150. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol. 2009 Jul 01; 183(1):75-82. Esensten JH, Lee MR, Glimcher LH, Bluestone JA. PMID: 19535634.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    151. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut. 2009 Oct; 58(10):1363-73. Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone JA, Moser M. PMID: 19505881.
      View in: PubMed   Mentions: 26     Fields:    Translation:AnimalsCells
    152. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009 Jun; 21(3):281-5. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. PMID: 19500966.
      View in: PubMed   Mentions: 146     Fields:    Translation:HumansAnimalsCells
    153. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug; 132(2):166-73. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group . PMID: 19443276.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    154. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev. 2009 May; 229(1):41-66. Bour-Jordan H, Bluestone JA. PMID: 19426214.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansAnimalsCells
    155. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med. 2009 Mar 16; 206(3):507-14. Louvet C, Kabre BG, Davini DW, Martinier N, Su MA, DeVoss JJ, Rosenthal WL, Anderson MS, Bour-Jordan H, Bluestone JA. PMID: 19221395.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    156. The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients. Clin Immunol. 2009 Apr; 131(1):139-44. Su MA, Stenerson M, Liu W, Putnam A, Conte F, Bluestone JA, Anderson MS. PMID: 19150256.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    157. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009 Mar; 58(3):652-62. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. PMID: 19074986.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCells
    158. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci. 2008 Dec; 1150:300-10. You S, Alyanakian MA, Segovia B, Damotte D, Bluestone J, Bach JF, Chatenoud L. PMID: 19120317.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    159. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008 Dec 02; 105(48):18895-900. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. PMID: 19015530.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansAnimalsCells
    160. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008 Oct; 8(10):2086-96. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. PMID: 18828769.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCellsCTClinical Trials
    161. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008 Oct 23; 455(7216):1109-13. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. PMID: 18806780.
      View in: PubMed   Mentions: 781     Fields:    Translation:AnimalsCells
    162. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2008 Sep 01; 205(9):1983-91. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. PMID: 18725525.
      View in: PubMed   Mentions: 253     Fields:    Translation:AnimalsCells
    163. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol. 2008 Nov; 28(6):677-84. Bluestone JA, Tang Q, Sedwick CE. PMID: 18716861.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    164. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 2008 Nov; 57(11):3013-24. Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH. PMID: 18689692.
      View in: PubMed   Mentions: 72     Fields:    Translation:AnimalsCells
    165. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug; 224:166-82. Fife BT, Bluestone JA. PMID: 18759926.
      View in: PubMed   Mentions: 267     Fields:    Translation:HumansAnimalsCells
    166. Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol. 2008 Jun 15; 180(12):7793-803. Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone JA. PMID: 18523243.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    167. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev. 2008 Jun; 223:371-90. Brusko TM, Putnam AL, Bluestone JA. PMID: 18613848.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansAnimalsCells
    168. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008 May; 28(5):687-97. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. PMID: 18468463.
      View in: PubMed   Mentions: 354     Fields:    Translation:AnimalsCells
    169. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med. 2008 May; 14(5):528-35. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. PMID: 18438416.
      View in: PubMed   Mentions: 96     Fields:    Translation:AnimalsCells
    170. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur J Immunol. 2008 Apr; 38(4):931-4. Brusko T, Bluestone J. PMID: 18395864.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    171. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008 Mar; 9(3):239-44. Tang Q, Bluestone JA. PMID: 18285775.
      View in: PubMed   Mentions: 390     Fields:    Translation:HumansAnimalsCells
    172. Safer, longer-lasting regulatory T cells with beta-catenin. Nat Med. 2008 Feb; 14(2):118-9. Bluestone JA, Hebrok M. PMID: 18256611.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    173. Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes. 2008 Apr; 57(4):958-66. Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, Evan GI, Bluestone JA, Hebrok M. PMID: 18083786.
      View in: PubMed   Mentions: 53     Fields:    Translation:AnimalsCells
    174. B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest. 2007 Dec; 117(12):3642-5. Bour-Jordan H, Bluestone JA. PMID: 18060022.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    175. Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp. 2007; (9):404. Szot GL, Koudria P, Bluestone JA. PMID: 18989445.
      View in: PubMed   Mentions: 37     Fields:    Translation:Animals
    176. Murine pancreatic islet isolation. J Vis Exp. 2007; (7):255. Szot GL, Koudria P, Bluestone JA. PMID: 18989427.
      View in: PubMed   Mentions: 62     Fields:    Translation:Animals
    177. Regulatory T cells: therapeutic potential for treating transplant rejection and type I diabetes. J Vis Exp. 2007; (7):257. Bluestone JA. PMID: 18989429.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    178. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature. 2007 Sep 20; 449(7160):361-5. Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D. PMID: 17694047.
      View in: PubMed   Mentions: 248     Fields:    Translation:AnimalsCells
    179. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 2007 Nov; 148(11):5136-44. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC. PMID: 17673522.
      View in: PubMed   Mentions: 66     Fields:    Translation:AnimalsCells
    180. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol. 2007 08; 7(8):650-4. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. PMID: 17653127.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    181. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol. 2007 Aug; 7(8):622-32. Chatenoud L, Bluestone JA. PMID: 17641665.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansAnimalsCells
    182. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol. 2007 Jul 15; 179(2):1004-12. Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone JA. PMID: 17617592.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    183. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol. 2007 Oct; 125(1):16-25. Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH. PMID: 17627890.
      View in: PubMed   Mentions: 40     Fields:    Translation:AnimalsCells
    184. Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol. 2007 May; 37(5):1285-9. Chikuma S, Bluestone JA. PMID: 17429849.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    185. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A. 2007 Apr 10; 104(15):6335-40. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. PMID: 17389382.
      View in: PubMed   Mentions: 71     Fields:    Translation:AnimalsCells
    186. New reagents on the horizon for immune tolerance. Annu Rev Med. 2007; 58:329-46. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J. PMID: 16987079.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic Health
    187. Sensory neurons link the nervous system and autoimmune diabetes. Cell. 2006 Dec 15; 127(6):1097-9. Bour-Jordan H, Bluestone JA. PMID: 17174888.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    188. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med. 2006 Nov 27; 203(12):2737-47. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. PMID: 17116737.
      View in: PubMed   Mentions: 149     Fields:    Translation:AnimalsCells
    189. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28; 355(13):1318-30. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. PMID: 17005949.
      View in: PubMed   Mentions: 576     Fields:    Translation:HumansCTClinical Trials
    190. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006 Sep; 55(9):2588-94. Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC. PMID: 16936208.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    191. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006 Aug 01; 177(3):1451-9. Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. PMID: 16849451.
      View in: PubMed   Mentions: 86     Fields:    Translation:AnimalsCells
    192. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest. 2006 Aug; 116(8):2252-61. Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA. PMID: 16886063.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    193. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev. 2006 Aug; 212:217-37. Tang Q, Bluestone JA. PMID: 16903917.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    194. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006 Jul 10; 203(7):1701-11. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. PMID: 16818678.
      View in: PubMed   Mentions: 903     Fields:    Translation:HumansCells
    195. Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nat Immunol. 2006 Jun; 7(6):551-3. Tang Q, Bluestone JA. PMID: 16715063.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    196. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest. 2006 May; 116(5):1371-81. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M. PMID: 16628253.
      View in: PubMed   Mentions: 116     Fields:    Translation:AnimalsCells
    197. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006 Mar; 24(3):233-8. Bluestone JA, St Clair EW, Turka LA. PMID: 16546089.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimalsCells
    198. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol. 2006 Apr; 18(2):103-10. Masteller EL, Tang Q, Bluestone JA. PMID: 16458533.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    199. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol. 2006 Jan; 7(1):83-92. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA. PMID: 16311599.
      View in: PubMed   Mentions: 305     Fields:    Translation:AnimalsCells
    200. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005 Nov 21; 202(10):1375-86. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. PMID: 16287710.
      View in: PubMed   Mentions: 120     Fields:    Translation:AnimalsCells
    201. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol. 2005 Nov 01; 175(9):5649-55. Bour-Jordan H, Thompson HL, Bluestone JA. PMID: 16237054.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    202. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol. 2005 Dec; 17(6):638-42. Bluestone JA, Tang Q. PMID: 16209918.
      View in: PubMed   Mentions: 81     Fields:    Translation:AnimalsCells
    203. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct; 115(10):2904-13. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. PMID: 16167085.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCells
    204. A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas. J Immunol. 2005 Sep 15; 175(6):3621-7. Dai YD, Jensen KP, Lehuen A, Masteller EL, Bluestone JA, Wilson DB, Sercarz EE. PMID: 16148106.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    205. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol. 2005 Sep 01; 175(5):3053-9. Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA. PMID: 16116193.
      View in: PubMed   Mentions: 73     Fields:    Translation:AnimalsCells
    206. Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol. 2005 Sep-Dec; 24(5-6):287-305. Chen W, Bluestone JA, Herold KC. PMID: 16318983.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    207. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity. 2005 Aug; 23(2):115-26. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT. PMID: 16111631.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansAnimals
    208. B7-independent inhibition of T cells by CTLA-4. J Immunol. 2005 Jul 01; 175(1):177-81. Chikuma S, Abbas AK, Bluestone JA. PMID: 15972645.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    209. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun; 54(6):1763-9. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. PMID: 15919798.
      View in: PubMed   Mentions: 217     Fields:    Translation:HumansCTClinical Trials
    210. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J Immunol. 2005 May 01; 174(9):5298-305. Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, Bluestone JA, Beissert S. PMID: 15843526.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    211. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol. 2005 Apr 15; 174(8):4525-34. Kohm AP, Williams JS, Bickford AL, McMahon JS, Chatenoud L, Bach JF, Bluestone JA, Miller SD. PMID: 15814673.
      View in: PubMed   Mentions: 38     Fields:    Translation:AnimalsCells
    212. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol. 2005 Apr 15; 174(8):4696-705. Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S. PMID: 15814694.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    213. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol. 2005 04; 5(4):343-9. Bluestone JA. PMID: 15775994.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    214. CTLA-4Ig is finally making it: a personal perspective. Am J Transplant. 2005 Mar; 5(3):423-4. Bluestone JA. PMID: 15707394.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    215. Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus. Rev Diabet Stud. 2004; 1(4):156-64. Boehm BO, Bluestone JA. PMID: 17491700.
      View in: PubMed   Mentions: 2     Fields:    
    216. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005; 23:447-85. Anderson MS, Bluestone JA. PMID: 15771578.
      View in: PubMed   Mentions: 421     Fields:    Translation:AnimalsCells
    217. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004 Nov; 34(11):2996-3005. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. PMID: 15468055.
      View in: PubMed   Mentions: 132     Fields:    Translation:AnimalsCells
    218. Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. Clin Immunol. 2004 Oct; 113(1):29-37. Judkowski V, Rodriguez E, Pinilla C, Masteller E, Bluestone JA, Sarvetnick N, Wilson DB. PMID: 15380527.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    219. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest. 2004 Oct; 114(7):979-87. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA. PMID: 15467837.
      View in: PubMed   Mentions: 66     Fields:    Translation:AnimalsCells
    220. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A. 2004 Oct 05; 101 Suppl 2:14622-6. Bluestone JA, Tang Q. PMID: 15322272.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    221. CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. J Immunol. 2004 Jun 15; 172(12):7442-50. Eagar TN, Turley DM, Padilla J, Karandikar NJ, Tan L, Bluestone JA, Miller SD. PMID: 15187122.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    222. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004 Jun 07; 199(11):1455-65. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. PMID: 15184499.
      View in: PubMed   Mentions: 403     Fields:    Translation:AnimalsCells
    223. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity. 2004 Jun; 20(6):757-67. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL. PMID: 15189740.
      View in: PubMed   Mentions: 124     Fields:    Translation:AnimalsCells
    224. Notch signaling in lymphocyte development and function. Curr Opin Immunol. 2004 Jun; 16(3):360-6. Robey EA, Bluestone JA. PMID: 15134786.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    225. Notch 1 signaling regulates peripheral T cell activation. Immunity. 2004 Apr; 20(4):407-15. Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA. PMID: 15084270.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    226. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004 Mar; 4(3):390-401. Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA. PMID: 14961992.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    227. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. J Immunol. 2004 Feb 01; 172(3):1449-54. Jovasevic VM, Gorelik L, Bluestone JA, Mokyr MB. PMID: 14734721.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    228. Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb; 53(2):426-33. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. PMID: 14747294.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    229. Beta-cell replacement for type I diabetes. Annu Rev Med. 2004; 55:133-56. Stock PG, Bluestone JA. PMID: 14746513.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    230. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol. 2003 Nov 15; 171(10):5587-95. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA. PMID: 14607967.
      View in: PubMed   Mentions: 33     Fields:    Translation:AnimalsCells
    231. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol. 2003 Oct 01; 171(7):3348-52. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. PMID: 14500627.
      View in: PubMed   Mentions: 219     Fields:    Translation:AnimalsCells
    232. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med. 2003 Sep; 9(9):1202-8. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L. PMID: 12937416.
      View in: PubMed   Mentions: 202     Fields:    Translation:AnimalsCells
    233. Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm Res. 2003 Aug; 20(8):1239-48. Park CG, Thiex NW, Lee KM, Szot GL, Bluestone JA, Lee KD. PMID: 12948022.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    234. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant. 2003 Jul; 3(7):794-803. Matthews JB, Ramos E, Bluestone JA. PMID: 12814471.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    235. Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis. J Clin Invest. 2003 Jun; 111(12):1923-31. Ding W, Beissert S, Deng L, Miranda E, Cassetty C, Seiffert K, Campton KL, Yan Z, Murphy GF, Bluestone JA, Granstein RD. PMID: 12813028.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    236. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003 Mar; 3(3):253-7. Bluestone JA, Abbas AK. PMID: 12658273.
      View in: PubMed   Mentions: 403     Fields:    Translation:HumansAnimalsCells
    237. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003 Feb; 111(3):409-18. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. PMID: 12569167.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    238. CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J Immunol. 2003 Feb 01; 170(3):1510-6. Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, Henriksen KJ, Thompson CB, Bluestone JA. PMID: 12538715.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    239. Directed evolution of a single-chain class II MHC product by yeast display. Protein Eng. 2003 Feb; 16(2):147-56. Starwalt SE, Masteller EL, Bluestone JA, Kranz DM. PMID: 12676983.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    240. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol. 2003 Feb; 4(2):182-8. Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. PMID: 12524538.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    241. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2003 Jan 06; 197(1):129-35. Chikuma S, Imboden JB, Bluestone JA. PMID: 12515820.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    242. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity. 2003 Jan; 18(1):41-51. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL. PMID: 12530974.
      View in: PubMed   Mentions: 111     Fields:    Translation:AnimalsCells
    243. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp. 2003; 252:55-63; discussion 63-6, 106-14. Boden E, Tang Q, Bour-Jordan H, Bluestone JA. PMID: 14609212.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    244. CTLA-4 and tolerance: the biochemical point of view. Immunol Res. 2003; 28(3):241-53. Chikuma S, Bluestone JA. PMID: 14713717.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    245. When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol. 2002 Nov; 3(11):1056-7. Finger EB, Bluestone JA. PMID: 12407416.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    246. Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol. 2002 Oct; 14(5):652-9. Masteller EL, Bluestone JA. PMID: 12183168.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    247. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002 Sep; 29(9):1907-13. Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR. PMID: 12233885.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    248. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002 Jul 15; 169(2):633-7. Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML. PMID: 12097362.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    249. The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol. 2002 Jul; 110(1):17-23. Rotrosen D, Matthews JB, Bluestone JA. PMID: 12110811.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    250. CTLA-4: acting at the synapse. Mol Interv. 2002 Jul; 2(4):205-8. Chikuma S, Bluestone JA. PMID: 14993389.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    251. Inability to induce tolerance through direct antigen presentation. Am J Transplant. 2002 Jul; 2(6):510-9. Rulifson IC, Szot GL, Palmer E, Bluestone JA. PMID: 12118894.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    252. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30; 346(22):1692-8. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. PMID: 12037148.
      View in: PubMed   Mentions: 386     Fields:    Translation:HumansCTClinical Trials
    253. The Src family kinase Fyn mediates signals induced by TCR antagonists. J Immunol. 2002 May 01; 168(9):4480-7. Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. PMID: 11970992.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    254. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol. 2002 04; 32(4):972-81. Eagar TN, Karandikar NJ, Bluestone JA, Miller SD. PMID: 11920563.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCellsPHPublic Health
    255. The immune tolerance network: the "Holy Grail" comes to the clinic. J Am Soc Nephrol. 2000 Nov; 11(11):2141-2146. Bluestone JA, Matthews JB, Krensky AM. PMID: 11053493.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    Jeffrey's Networks
    Concepts (672)
    Derived automatically from this person's publications.
    _
    Co-Authors (94)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _